Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.
暂无分享,去创建一个
S. Shen | R. Meredith | S. Knox | A. Lobuglio | J. Shah | A. Forero-Torres | C. Vaklavas | I. Micallef